The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Preparing for the NASH epidemic: A call to action
Metabolism. 2021 Jul 6;154822. doi: 10.1016/j.metabol.2021.154822. Online ahead of print.
Fasiha Kanwal1, Jay H Shubrook2, Zobair Younossi3, Yamini Natarajan4, Elisabetta Bugianesi5, Mary E Rinella6, Stephen A Harrison7, Christos Mantzoros8, Kim Pfotenhauer9, Samuel Klein10, Robert H Eckel11, Davida Kruger12, Hashem El-Serag4, Kenneth Cusi13
Author information
1Baylor College of Medicine, Veterans Affairs Health Services Research and Development Service, Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States of America.
2Touro University California, College of Osteopathic Medicine, Vallejo, CA, United States of America.
3Inova Health System, Falls Church, VA, United States of America.
4Baylor College of Medicine, Houston, TX, United States of America.
5University of Turin, Turin, Italy.
6Northwestern University, Chicago, IL, United States of America.
7Pinnacle Clinical Research, San Antonio, TX, United States of America.
8Harvard Medical School, Boston, MA, United States of America.
9Michigan State University, East Lansing, MI, United States of America.
10Washington University School of Medicine, St Louis, MO, United States of America.
11University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.
12Henry Ford Health System, Detroit, MI, United States of America.
13University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, FL, United States of America. Electronic address: Kenneth.cusi@medicine.ufl.edu.
Abstract
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common conditions with a rising burden. Yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single global guiding strategy for the management of NAFLD and NASH. The American Gastroenterological Association, in collaboration with 7 professional associations, convened an international conference comprising 32 experts in gastroenterology, hepatology, endocrinology, and primary care providers from the United States, Europe, Asia, and Australia. Conference content was informed by the results of a national NASH Needs Assessment Survey. The participants reviewed and discussed published literature on global burden, screening, risk stratification, diagnosis, and management of individuals with NAFLD, including those with NASH. Participants identified promising approaches for clinical practice and prepared a comprehensive, unified strategy for primary care providers and relevant specialists encompassing the full spectrum of NAFLD/NASH care. They also identified specific high-yield targets for clinical research and called for a unified, international public health response to NAFLD and NASH.